The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple, Fast, and Accurate Algorithm to Estimate Large Phylogenies by Maximum Likelihood
Guindon, S., & Gascuel, O. (2003) · Systematic Biology · doi:10.1080/10635150390235520 · Cited by 16,806
MUSCLE: a multiple sequence alignment method with reduced time and space complexity
Edgar, R. C. (2004) · BMC Bioinformatics · doi:10.1186/1471-2105-5-113 · Cited by 8,970
Multiple Comparisons of Log-Likelihoods with Applications to Phylogenetic Inference
Shimodaira, H., & Hasegawa, M. (1999) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a026201 · Cited by 4,237
PHYLIP ( PHYLogeny Inference Package)
Cummings, M. P. (2004) · Dictionary of Bioinformatics and Computational Biology · doi:10.1002/9780471650126.dob0534.pub2 · Cited by 3,127
ProtTest: selection of best-fit models of protein evolution
Abascal, F., Zardoya, R., & Posada, D. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti263 · Cited by 3,063
Whelan, S., & Goldman, N. (2001) · Molecular Biology and Evolution · doi:10.1093/oxfordjournals.molbev.a003851 · Cited by 2,849
TREE-PUZZLE: maximum likelihood phylogenetic analysis using quartets and parallel computing
Schmidt, H. A., Strimmer, K., Vingron, M., & von Haeseler, A. (2002) · Bioinformatics · doi:10.1093/bioinformatics/18.3.502 · Cited by 2,532
SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and molecular phylogeny
Galtier, N., Gouy, M., & Gautier, C. (1996) · Bioinformatics · doi:10.1093/bioinformatics/12.6.543 · Cited by 2,263
PHYLIP (Phylogeny Inference Package)
Cummings, M. P. (2004) · Dictionary of Bioinformatics and Computational Biology · doi:10.1002/0471650129.dob0534 · Cited by 1,967
Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences
Mammalian Gene Collection (MGC) Program Team* (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242603899 · Cited by 1,749
Cited by
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Indoleamine 2,3 dioxygenase and metabolic control of immune responses
Munn, D. H., & Mellor, A. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.001 · Cited by 1,037
Kynurenine pathway metabolism and the microbiota-gut-brain axis
Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.002 · Cited by 724
“IDO1 is the best characterised of these IDO enzymes in converting tryptophan to kynurenine both in the GI tract and other tissues of the body (Ciorba, 2013) although our knowledge of the more recently discovered IDO2 is steadily increasing (Ball et al., 2007; Fatokun et al., 2013).”
BackgroundKynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Baban, B., Chandler, P. R., Sharma, M. D., Pihkala, J., Koni, P. A., Munn, D. H., & Mellor, A. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900986 · Cited by 499
Metz, R., DuHadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J., & Prendergast, G. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1872 · Cited by 467
Innate immunity to Toxoplasma gondii infection
Yarovinsky, F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3598 · Cited by 462
IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation
Puccetti, P., & Grohmann, U. (2007) · Nature Reviews Immunology · doi:10.1038/nri2163 · Cited by 453
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?
Löb, S., Königsrainer, A., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2639 · Cited by 421
Indoleamine 2,3‐dioxygenase in T‐cell tolerance and tumoral immune escape
Katz, J. B., Muller, A. J., & Prendergast, G. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00610.x · Cited by 398
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Inflammation, vitamin B6 and related pathways
Ueland, P. M., McCann, A., Midttun, Ø., & Ulvik, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.08.001 · Cited by 382
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Tang, K., Wu, Y.-H., Song, Y., & Yu, B. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01080-8 · Cited by 365
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity
Mbongue, J., Nicholas, D., Torrez, T., Kim, N.-S., Firek, A., & Langridge, W. (2015) · Vaccines · doi:10.3390/vaccines3030703 · Cited by 351
“remains unclear, and unlike IDO1, its expression is not induced by virus infection or the presence of IFN [4].”
BackgroundTargeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Immune escape as a fundamental trait of cancer: focus on IDO
Prendergast, G. C. (2008) · Oncogene · doi:10.1038/onc.2008.35 · Cited by 325
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 308
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 304
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
O'Connor, J. C., Lawson, M. A., André, C., Briley, E. M., Szegedi, S. S., Lestage, J., Castanon, N., Herkenham, M., Dantzer, R., & Kelley, K. W. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802722 · Cited by 295
D'Amato, N. C., Rogers, T. J., Gordon, M. A., Greene, L. I., Cochrane, D. R., Spoelstra, N. S., Nemkov, T. G., D'Alessandro, A., Hansen, K. C., & Richer, J. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2011 · Cited by 294
Blood-brain barrier permeability and physical exercise
Małkiewicz, M. A., Szarmach, A., Sabisz, A., Cubała, W. J., Szurowska, E., & Winklewski, P. J. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1403-x · Cited by 276
Favennec, M., Hennart, B., Caiazzo, R., Leloire, A., Yengo, L., Verbanck, M., Arredouani, A., Marre, M., Pigeyre, M., Bessede, A., et al. (2015) · Obesity · doi:10.1002/oby.21199 · Cited by 276
Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway
Ball, H. J., Yuasa, H. J., Austin, C. J. D., Weiser, S., & Hunt, N. H. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.01.005 · Cited by 275
Self-citationThe rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
Brochez, L., Chevolet, I., & Kruse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 270
Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., & Young, J. W. (2009) · Blood · doi:10.1182/blood-2008-11-191197 · Cited by 262
Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
Muller, A. J., Manfredi, M. G., Zakharia, Y., & Prendergast, G. C. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0702-0 · Cited by 262
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Parrott, J. M., Redus, L., & O’Connor, J. C. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0590-y · Cited by 112
“In the hippocampus and amygdala, IDO2 expression decreased at 24 h following LPS while otherwise remaining unchanged, which follows conflicting previous studies demonstrating that proinflammatory stimuli increased or had no impact on IDO2 mRNA [60, 61].”
ResultBlumenthal, A., Nagalingam, G., Huch, J. H., Walker, L., Guillemin, G. J., Smythe, G. A., Ehrt, S., Britton, W. J., & Saunders, B. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037314 · Cited by 105
Metadata
- Authors
- Ball, H. J., Sanchez-Perez, A., Weiser, S., Austin, C. J. D., Astelbauer, F., Miu, J., McQuillan, J. A., Stocker, R., Jermiin, L. S., & Hunt, N. H.
- Venue
- Gene
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 396
- Issue
- 1
- Pages
- 203-213
- ISSN
- 0378-1119 (ISSN-L)
- OpenAlex
- W2053217888
- Cited by
- 434
- References
- 49
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.